HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A corrigendum has been published Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by ALLGULANDER, C. Articles by SALINAS, E. Search for Related Content PubMed PubMed Citation Articles by ALLGULANDER, C. Articles by SALINAS, E.

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder

Twenty-four-week placebo-controlled dose-ranging study

Neurotec/Psychiatry, Huddinge University Hospital, Huddinge, Sweden

DAVID HACKETT, MSc and ELISEO SALINAS, MD

Wyeth-Ayerst Research, CNS Department, Puteaux, Paris, France

Correspondence: Dr C. Allgulander, Neurotec/Psychiatry, M57 Huddinge University Hospital, S-14186 Huddinge, Sweden

Declaration of interest This study was funded by Wyeth-Ayerst Research, of which D.H. and E.S. are employees. C. A. is an employee of the Karolinska Institutet, Stockholm, and was an investigator for one study centre.

Background Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.

Aims To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.

Method A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.

Results All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.

Conclusions Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.

This article has been cited by other articles:

				D Nutt, C Allgulander, Y Lecrubier, T Peters, and U Wittchen Establishing non-inferiority in treatment trials in psychiatry -- guidelines from an Expert Consensus Meeting J Psychopharmacol, June 1, 2008; 22(4): 409 - 416. [Abstract] [PDF]

				R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson An effect-size analysis of pharmacologic treatments for generalized anxiety disorder J Psychopharmacol, November 1, 2007; 21(8): 864 - 872. [Abstract] [PDF]

				References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]

				M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials Am J Psychiatry, February 1, 2007; 164(2): 290 - 300. [Abstract] [Full Text] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				M. R. Liebowitz, A. J. Gelenberg, and D. Munjack Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder Arch Gen Psychiatry, February 1, 2005; 62(2): 190 - 198. [Abstract] [Full Text] [PDF]

				C. Allgulander, A. A. Dahl, C. Austin, P. L.P. Morris, J. A. Sogaard, R. Fayyad, S. P. Kutcher, and C. M. Clary Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder Am J Psychiatry, September 1, 2004; 161(9): 1642 - 1649. [Abstract] [Full Text] [PDF]

				A. K. Jainer, S. Acharya, C. Allgulander, D. Hackett, and E. O. Salinas Reporting of randomised trials Authors' reply The British Journal of Psychiatry, February 1, 2002; 180(2): 185 - 186. [Full Text] [PDF]

				I. C. Wright, M. E. Thase, G. Jackson, T. Brown, J. Butler, P. Cowen, C. Freeman, H. Freeman, L. Gask, G. Kassianos, et al. Conflict of interest and the British Journal of Psychiatry Author's reply Response from Neurolink Editor's response The British Journal of Psychiatry, January 1, 2002; 180(1): 82 - 83. [Full Text] [PDF]